Centre of Excellence for Cellular Therapy
Dr Denis Claude Roy and the Centre of Excellence for Cellular Therapy are pivotal in the development of Kiadis Pharma’s ATIR™. This is a novel immunotherapeutic strategy for 40% of patients who suffer from blood cancer and who do not have a standard of care stem cell donor available. ATIR™ enables hematopoietic stem cell transplantations using partially mismatched family members as donors to address this unmet medical need.
CellCAN is a Canadian network focused on advancing cell and gene therapy manufacturing under GMP through the deployment of standards for training that implement best practices.